ATM (Ab-1981) Antibody

What are the validated applications for ATM (Ab-1981) Antibody?

The ATM (Ab-1981) Antibody has been validated for Western blotting (WB) and immunofluorescence (IF) applications . For Western blotting, the antibody effectively detects the ATM protein at approximately 370 kDa under reducing conditions. When conducting immunofluorescence studies, the antibody allows visualization of ATM's subcellular localization, which typically shows predominantly nuclear distribution with some cytoplasmic presence. It is important to note that while these are the validated applications, optimization may be required for specific experimental systems, particularly when working with different cell types or tissue samples.

How does ATM (Ab-1981) Antibody differ from phospho-specific ATM antibodies?

The ATM (Ab-1981) Antibody differs fundamentally from phospho-specific ATM antibodies in target recognition and experimental utility. While ATM (Ab-1981) detects total ATM protein regardless of its activation state , phospho-specific antibodies such as Anti-Phospho-ATM (S1981) antibodies recognize ATM only when phosphorylated at serine 1981, a modification associated with ATM activation in response to DNA damage .

When investigating the DNA damage response pathway, researchers often use both antibody types in parallel: total ATM antibodies to normalize for protein expression levels, and phospho-specific antibodies to assess activation status. This complementary approach provides a more complete picture of ATM biology in experimental contexts. When phospho-ATM (S1981) antibodies show signal increases while total ATM remains constant, this indicates ATM activation rather than upregulation.

What is the appropriate sample preparation for optimal results with ATM (Ab-1981) Antibody?

For optimal results with ATM (Ab-1981) Antibody, careful sample preparation is essential due to the large size of the ATM protein (370 kDa) and its relatively low abundance in many cell types. For Western blotting applications, cells should be lysed in a buffer containing appropriate protease inhibitors to prevent degradation. RIPA buffer supplemented with a complete protease inhibitor cocktail is generally effective, though some researchers prefer NP-40 buffer for gentler extraction.

When preparing samples for immunofluorescence, fixation with 4% paraformaldehyde followed by permeabilization with 0.1-0.5% Triton X-100 typically yields good results. Importantly, heat-induced epitope retrieval may be necessary when working with formalin-fixed paraffin-embedded tissues. The antibody requires a working concentration of approximately 1-5 μg/ml for most applications, though this should be optimized for each experimental system .

How should researchers design control experiments when using ATM (Ab-1981) Antibody?

Designing appropriate controls is critical when using the ATM (Ab-1981) Antibody to ensure experimental validity. A comprehensive control strategy should include the following elements: (1) A negative control using ATM-null or ATM-knockdown cells to confirm antibody specificity; (2) A blocking peptide control, where the immunizing peptide is pre-incubated with the antibody to demonstrate binding specificity; (3) A loading control antibody targeting a housekeeping protein appropriate for your experimental system; and (4) A positive control using cells with known ATM expression levels.

For DNA damage response studies, researchers should include both untreated controls and time-course treatments with DNA-damaging agents like camptothecin or ionizing radiation . This approach helps distinguish between basal and induced ATM states. Additionally, comparing signals from both ATM (Ab-1981) Antibody and phospho-specific ATM antibodies provides a more complete picture of ATM regulation in response to experimental manipulations.

What are the optimal dilutions and incubation conditions for different applications?

The optimal working conditions for ATM (Ab-1981) Antibody vary depending on the application and experimental system. For Western blotting, initial testing should begin with a 1:500 to 1:1000 dilution in 5% BSA or non-fat milk in TBST, with overnight incubation at 4°C . For immunofluorescence applications, a starting dilution of 1:100 to 1:200 in antibody diluent with overnight incubation at 4°C is recommended.

When optimizing dilutions, it's advisable to perform a titration experiment testing several concentrations to identify the dilution that provides the best signal-to-noise ratio for your specific experimental system. Incubation times may also require adjustment, with some systems showing better results with longer primary antibody incubations (up to 48 hours at 4°C) for detecting low-abundance targets like ATM. Secondary antibody selection should be compatible with the detection method and optimized separately.

How can researchers troubleshoot weak or absent signals when using ATM (Ab-1981) Antibody?

When troubleshooting weak or absent signals with ATM (Ab-1981) Antibody, consider the following methodological approaches:

• Protein Extraction Efficiency: ATM is a large nuclear protein that may require optimized extraction methods. Try using different lysis buffers (RIPA vs. NP-40) or adding sonication steps to improve nuclear protein extraction.

• Protein Transfer Issues: For Western blotting, the large size of ATM (370 kDa) makes efficient transfer challenging. Extended transfer times (up to overnight) or specialized transfer systems for high molecular weight proteins may be necessary.

• Antibody Concentration: If signal is weak, try increasing the antibody concentration or extending incubation times. For some applications, signal amplification systems may be beneficial.

• Sample Degradation: ATM is susceptible to proteolytic degradation. Ensure fresh samples are used with complete protease inhibitor cocktails, and minimize freeze-thaw cycles of both samples and antibody.

• Epitope Masking: In some experimental conditions, protein-protein interactions or post-translational modifications may mask the antibody epitope. Adjusting fixation protocols or denaturing conditions may help expose the epitope.

If signals remain problematic after these adjustments, consider validating your experimental system with a different ATM antibody targeting a different epitope to confirm whether the issue is antibody-specific or related to ATM expression in your samples.

How should researchers interpret differences between total ATM (Ab-1981) signals and phospho-ATM (S1981) signals?

Interpreting the relationship between total ATM and phospho-ATM signals requires careful consideration of their biological significance. When total ATM levels (detected by Ab-1981) remain constant while phospho-ATM (S1981) signals increase, this typically indicates ATM activation in response to DNA damage or other cellular stresses rather than upregulation of ATM expression . This pattern is commonly observed in early responses to DNA-damaging agents.

What are the methodological considerations for studying ATM activation kinetics?

Studying ATM activation kinetics requires careful experimental design that captures both temporal and spatial aspects of ATM regulation. A comprehensive methodological approach should include:

• Time-course experiments: Collect samples at multiple timepoints (e.g., 5, 15, 30, 60, 120 minutes, and 24 hours) after treatment with DNA-damaging agents to capture both rapid phosphorylation and potential dephosphorylation phases.

• Dose-response analysis: Vary the intensity of stimulus (e.g., different doses of ionizing radiation or chemical agents) to assess threshold effects in ATM activation.

• Subcellular fractionation: Separate nuclear and cytoplasmic fractions to track ATM localization changes during activation.

• Co-immunoprecipitation: Assess changes in ATM interaction partners during activation phases using the ATM (Ab-1981) Antibody for pulldown experiments.

• Parallel analysis of downstream targets: Monitor phosphorylation of ATM substrates (e.g., p53, CHK2) to correlate ATM activation with functional outcomes.

Western blotting with both total ATM (Ab-1981) and phospho-specific antibodies provides quantitative data for generating activation curves . For single-cell resolution, immunofluorescence can reveal population heterogeneity in activation responses that might be masked in bulk analyses.

How can researchers validate ATM antibody specificity in their experimental systems?

Validating ATM antibody specificity is crucial for ensuring experimental rigor. A comprehensive validation strategy should employ multiple complementary approaches:

• Genetic validation: Test antibody reactivity in ATM-knockout or ATM-knockdown models compared to wild-type controls. A specific antibody should show significantly reduced or absent signal in ATM-deficient samples.

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide before application to samples. Specific binding should be blocked, resulting in signal reduction.

• Immunoprecipitation-mass spectrometry: Perform IP with the ATM (Ab-1981) Antibody followed by mass spectrometry to confirm that ATM is indeed the captured protein.

• Comparison with alternative antibodies: Test multiple antibodies targeting different ATM epitopes to confirm consistent detection patterns.

• Phosphatase treatment: For comparison with phospho-specific antibodies, treat samples with lambda phosphatase to confirm that phospho-specific signals are truly phosphorylation-dependent while total ATM signals remain unaffected .

These validation approaches should be documented and reported in publications to enhance reproducibility and confidence in experimental findings.

What are the considerations for using ATM (Ab-1981) Antibody in multiplex immunofluorescence assays?

When incorporating ATM (Ab-1981) Antibody into multiplex immunofluorescence assays, researchers must address several technical challenges:

• Antibody compatibility: Ensure all primary antibodies in the multiplex panel are raised in different host species to avoid cross-reactivity of secondary antibodies. If using multiple rabbit antibodies, consider direct conjugation or sequential detection protocols.

• Signal optimization: ATM typically shows lower expression levels than many other proteins, potentially requiring signal amplification through tyramide signal amplification (TSA) or similar approaches.

• Spectral overlap: Choose fluorophores with minimal spectral overlap, particularly when simultaneously detecting total ATM and phospho-ATM, which often localize to the same subcellular compartments.

• Order of detection: When using sequential staining protocols, apply the ATM (Ab-1981) Antibody early in the sequence, as the antigen may be sensitive to multiple rounds of stripping or elution buffers.

• Controls for multiplexing: Include single-stain controls for each antibody to confirm that multiplexing doesn't alter individual staining patterns or intensities.

A carefully designed multiplex panel might include ATM (Ab-1981), phospho-ATM (S1981), DNA damage markers (γH2AX), and cell cycle phase indicators to comprehensively assess ATM activation in relation to cell cycle and DNA damage responses at the single-cell level.

How does sample preparation influence ATM epitope preservation and detection efficiency?

Sample preparation significantly impacts ATM epitope preservation and detection efficiency across different experimental approaches. The large size and nuclear localization of ATM make it particularly sensitive to preparation artifacts. For optimal results, consider the following preparation-specific guidelines:

For Western blotting:

• Nuclear extraction protocols often yield better results than whole-cell lysates

• Avoid excessive heating of samples, as ATM is heat-sensitive

• Use freshly prepared samples when possible, as freeze-thaw cycles can reduce signal intensity

• Add phosphatase inhibitors to preserve phosphorylated forms for comparison studies

For immunofluorescence:

• Paraformaldehyde (4%) fixation typically preserves ATM epitopes better than methanol fixation

• Gentle permeabilization (0.1-0.2% Triton X-100 for 5-10 minutes) helps maintain nuclear architecture

• Extended blocking (1-2 hours) with 5% normal serum can reduce background signal

• For tissue sections, antigen retrieval methods significantly impact epitope accessibility

For flow cytometry:

• Methanol permeabilization may improve nuclear accessibility compared to saponin-based methods

• Fix cells before permeabilization to better preserve nuclear proteins

• Consider non-detergent permeabilization methods for phospho-epitope preservation

Each preparation method creates a different microenvironment that can affect epitope conformation and accessibility, necessitating method-specific optimization of antibody concentration and incubation conditions.

What approaches can be used to correlate ATM activation with DNA damage response outcomes in complex experimental systems?

Correlating ATM activation with DNA damage response outcomes requires integrating multiple methodological approaches. A comprehensive experimental design might include the following elements:

• Temporal correlation analysis: Perform time-course experiments using both ATM (Ab-1981) and phospho-ATM (S1981) antibodies alongside markers for:

  • DNA damage persistence (γH2AX foci)

  • Cell cycle checkpoints (phospho-CHK1/CHK2)

  • Apoptosis markers (cleaved caspase-3, PARP cleavage)

  • DNA repair pathway activation (RAD51, 53BP1 foci)

• Single-cell correlation approaches: Employ multiparameter flow cytometry or imaging cytometry to correlate ATM activation with individual cell outcomes:

• Genetic modulation approaches: Compare wild-type cells with those expressing ATM variants (kinase-dead, phospho-site mutants) to establish causality between ATM activation and observed responses.

• Pharmacological interventions: Use ATM kinase inhibitors at different timepoints to determine when ATM activity is required for specific outcomes.

• Mathematical modeling: Develop quantitative models incorporating measured parameters to predict cell fate decisions based on ATM activation dynamics.

This integrated approach allows researchers to establish not just correlations but potential causal relationships between ATM activation patterns and cellular outcomes in response to genotoxic stress .

How does ATM (Ab-1981) Antibody compare to other commercially available total ATM antibodies?

The ATM (Ab-1981) Antibody offers distinct characteristics when compared to other commercially available total ATM antibodies. This antibody targets the epitope region around amino acids 1979-1983 (E-G-S-Q-S) , which is relatively close to the important S1981 autophosphorylation site. In contrast, many other total ATM antibodies target C-terminal regions (e.g., AA 2484-2748) or other distinct epitopes.

This epitope location difference creates important experimental considerations. The ATM (Ab-1981) Antibody's epitope proximity to the S1981 phosphorylation site means that detection may potentially be affected by phosphorylation-induced conformational changes or by the presence of interacting proteins near this region. This differs from C-terminal-targeting antibodies that detect regions less likely to undergo conformational changes during activation.

When selecting between available total ATM antibodies, researchers should consider:

• The experimental question (protein quantification vs. protein interactions)

• Sample type and preparation method

• Compatibility with simultaneous phospho-ATM detection

• Validated applications for specific antibody clones

Cross-validation with multiple antibodies targeting different epitopes provides the most robust experimental approach when studying ATM biology.

What considerations should guide the choice between polyclonal ATM (Ab-1981) Antibody and monoclonal phospho-ATM antibodies?

The choice between polyclonal ATM (Ab-1981) Antibody and monoclonal phospho-ATM antibodies should be guided by specific experimental objectives and technical considerations:

Polyclonal ATM (Ab-1981) Advantages:

• Detects total ATM regardless of phosphorylation state

• Often provides stronger signals due to recognition of multiple epitopes within the target region

• May be more tolerant of minor protein denaturation or fixation-induced epitope alterations

• Useful for normalizing total protein levels in activation studies

Monoclonal Phospho-ATM Advantages:

• Highly specific for particular phosphorylation states (e.g., S1981)

• Provides consistent lot-to-lot reproducibility

• Often exhibits lower background in immunohistochemistry applications

• Directly measures ATM activation rather than expression

For optimal experimental design, researchers should use both antibody types in parallel. This complementary approach allows normalization of activation signals to total protein levels, controlling for expression variations across samples. For instance, in radiation response studies, phospho-ATM/total ATM ratios provide more meaningful activation metrics than either measurement alone .

When phosphorylation site-specific effects are being studied, monoclonal phospho-specific antibodies are essential, while studies of ATM expression regulation benefit from the polyclonal total ATM antibody approach.